Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accuracy of Kampo Diagnostic Support System: Comparison With Certified Physicians of the Japan Society for Oriental Medicine.

The Tokai journal of experimental and clinical medicine·2026
Same author

B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysis.

Diabetes research and clinical practice·2026
Same author

Role of estimated salt intake and nutritional status in patients undergoing hemodialysis: a longitudinal analysis.

BMC nephrology·2026
Same author

Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Tolvaptan Improves the Diurnal Blood Pressure Profile in Patients with Hypertension and Autosomal Dominant Polycystic Kidney Disease.

American journal of hypertension·2026
Same author

Correction: Machine learning model for predicting the cold-heat pattern in Kampo medicine: a multicenter prospective observational study.

Frontiers in pharmacology·2026

Related Experiment Video

Updated: May 15, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Aliskiren induced remarkable hypertriglyceridemia.

Kengo Azushima1, Kouichi Tamura, Hiromichi Wakui

  • 1Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan. fqqxj908@ybb.ne.jp

Internal Medicine (Tokyo, Japan)
|December 22, 2012
PubMed
Summary
This summary is machine-generated.

Aliskiren, a medication for high blood pressure, can cause severe hypertriglyceridemia (high triglycerides) and kidney issues. Discontinuing the drug led to spontaneous improvement, suggesting it as an adverse drug event.

Related Experiment Videos

Last Updated: May 15, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Area of Science:

  • Pharmacology
  • Nephrology
  • Cardiology

Background:

  • Hypertension management is crucial, especially in patients with chronic kidney disease.
  • Aliskiren is a direct renin inhibitor used for hypertension.
  • Uncontrolled hypertension necessitates treatment adjustments.

Observation:

  • A 42-year-old male with chronic kidney disease experienced uncontrolled hypertension.
  • Treatment with aliskiren 150 mg/day was initiated.
  • Remarkable hypertriglyceridemia and elevated creatinine levels were observed six weeks post-initiation.

Findings:

  • Aliskiren treatment led to significant hypertriglyceridemia and elevated creatinine.
  • Discontinuation of aliskiren resulted in spontaneous improvement of these laboratory values.
  • Drug-induced lymphocyte stimulation test (DLST) was strongly positive for aliskiren, supporting an adverse drug event.

Implications:

  • This case highlights a potential adverse effect of aliskiren, specifically severe hypertriglyceridemia.
  • Clinicians should monitor triglyceride and creatinine levels in patients treated with aliskiren.
  • Early recognition and discontinuation of the causative agent are key to managing aliskiren-induced hypertriglyceridemia.